Palmeri S, Gebbia V, Russo A, Armata M G, Gebbia N, Rausa L
Sezione di Oncologia Clinica, Università di Palermo, Italy.
Br J Cancer. 1990 Mar;61(3):475-8. doi: 10.1038/bjc.1990.105.
Fifty patients affected by histologically confirmed gastrointestinal tract cancer (GTC) were treated with oral tegafur (TG) 1,000 mg m-2 p.o. on days 1-14 repeated after a 14 day interval. Out of 42 evaluable patients seven patients had a partial response (PR. 17%) with a median duration of 20.5 weeks, three had a minimal response (7%) with a median duration of 23.7 weeks, nine showed a stabilisation which lasted a median of 31.3 weeks, and 23 progressed (55%). No response was obtained in patients affected by carcinoma of the pancreas and the hepatobiliary system. All PRs were achieved in patients with metastatic disease to the liver. No response was seen in patients with bone, lung or nodal metastasis. Three PRs were obtained in patients resistant to 5-fluorouracil. The difference in survival between patients who achieved PR and those who had a stabilisation was not statistically significant. On the other hand the survival of patients with PR was significantly longer than that of patients who progressed. Oral TG was well tolerated by most patients. WHO grade 1-2 gastrointestinal and neurological toxicities were seen respectively in 36% and 25% of cases. Five patients had grade 3 nausea/vomiting and one had grade 3 diarrhoea. Our data suggest that oral TG is effective in the treatment of stomach and colorectal cancers.
50例经组织学确诊为胃肠道癌（GTC）的患者接受口服替加氟（TG）治疗，剂量为1000mg/m²，口服，第1 - 14天给药，间隔14天后重复给药。42例可评估患者中，7例部分缓解（PR，17%），中位缓解持续时间为20.5周；3例轻微缓解（7%），中位缓解持续时间为23.7周；9例病情稳定，中位稳定持续时间为31.3周；23例病情进展（55%）。胰腺癌和肝胆系统癌患者未出现缓解。所有部分缓解均出现在肝转移患者中。骨、肺或淋巴结转移患者未出现缓解。3例对5 - 氟尿嘧啶耐药的患者获得部分缓解。部分缓解患者与病情稳定患者的生存差异无统计学意义。另一方面，部分缓解患者的生存期明显长于病情进展患者。大多数患者对口服TG耐受性良好。WHO 1 - 2级胃肠道和神经毒性分别见于36%和25%的病例。5例患者出现3级恶心/呕吐，1例出现3级腹泻。我们的数据表明，口服TG对胃癌和结直肠癌治疗有效。
